Dipeptidyl peptidase-4 (DPP-4) may predict response to tralokinumab in patients with asthma Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016
LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
LATE-BREAKING ABSTRACT: The study of fibulin-1 as a novel biomarker in bronchial asthma and its association to disease severity Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
LATE-BREAKING ABSTRACT: Novel inhaled ROR/c inhibitor for potential treatment of COPD Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
LATE-BREAKING ABSTRACT: Biomarkers of ECM turnover and clinical relevant outcomes in COPD: Results of the multicenter PROMISE study Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015
LATE-BREAKING ABSTRACT: Anti-inflammatory effect of a novel inhaled dual PDE3/4 inhibitor RPL554 in man, a unique “first-in-class” drug for the treatment of COPD & asthma Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
LATE-BREAKING ABSTRACT: Serum IL-13 is a peripheral biomarker for Type 2 asthma Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
LATE-BREAKING ABSTRACT: Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Increased serum MMP-3 in severe asthma is associated with oral steroid use; data from U-BIOPRED and BIOAIR cohorts Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017
LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Dipeptidyl peptidase I (DPPI) cleaves surfactant protein D (SP-D): A mechanism for immune compromise in the lung Source: International Congress 2016 – Molecular immunology of the lung Year: 2016
LATE-BREAKING ABSTRACT: Interleukin-33 augments rhinovirus-induced type 2 immune responses in people with asthma, but not in healthy donors Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
LATE-BREAKING ABSTRACT: GLCCI1 rs37972 gene‘s polymorphism correlation with response to oral glucocorticosteroids treatment in severe asthmatics from the BIOAIR cohort Source: Annual Congress 2012 - Gene-environment treatment and asthma Year: 2012
Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
The role of histone deacetylase 2 (HDAC2) and glucocorticoid receptor (GR) isoforms α, β in patients with asthma–COPD overlap syndrome (ACOS) Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016
LATE-BREAKING ABSTRACT: Effects of rare SERPINA1 variants on emphysema and airtrapping in SPIROMICS Source: International Congress 2016 – Role of genetics and exposures in COPD and asthma Year: 2016
LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV568, a narrow spectrum kinase inhibitor, following repeat inhaled dosing in COPD patients Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
LATE-BREAKING ABSTRACT: Transcriptomic fingerprinting in severe adult-onset asthma shows type2-high and inflammatory-cell gene signatures in the U-BIOPRED cohort Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015
LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016